Monday, September 14, 2026

IBS Researchers Advance Conditional Gene Editing With Cross-Species Expansion of SCON System

Researchers at IBS expanded the SCON gene knockout technology, enhancing studies in zebrafish and human stem cells for precise gene control.

2026 Defense White Paper: Will North Korea Still Be Classified as an Enemy?

Minister Chung Dong-young discusses the upcoming Defense White Paper 2026, affirming North Korea's enemy status while advocating for peace.

WIMP Strategy: Trump Is STILL Clinging To Old Negotiations, And North Korea Told Him To ABANDON All Delusions

North Korea rejects U.S. sanctions, calling them ineffective and insists on recognition as a nuclear state for future dialogue.

Tag: ASCO

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Sillajen Presents Early BAL0891 Clinical Findings at ASCO 2026, Highlighting Safety and Early Anti-Cancer Activity

ShillaGen presented initial clinical research results of its cancer drug BAL0891 at ASCO, showcasing promising developments.

SillaJen’s Breakthrough Cancer BAL0891 Drug Set for ASCO 2026 Reveal

SillaJen's anticancer drug BAL0891 will be presented at the ASCO Annual Meeting, currently in Phase 1 trials for solid tumors and AML.

Cancer Gone for 3 Years? This New Drug Is Making It Happen

AbbVie's Epkinly shows 96% long-term complete remission in R/R large B-cell lymphoma patients, highlighting its effectiveness as a therapy.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.